Ethambutol: Difference between revisions

Jump to navigation Jump to search
Line 30: Line 30:
'''| [[Ethambutol hydrochloride labels and packages|Labels and Packages]]'''
'''| [[Ethambutol hydrochloride labels and packages|Labels and Packages]]'''


==Mechanism of Action==
 
 
==Mechanism of action==
Ethambutol is [[bacteriostatic]] against actively growing TB bacilli. It works by obstructing the formation of [[cell wall]]. [[Mycolic acid]]s attach to the 5'-hydroxyl groups of [[arabinose|<small>D</small>-arabinose]] residues of [[arabinogalactan]] and form mycolyl-arabinogalactan-peptidoglycan complex in the cell wall. It disrupts arabinogalactan synthesis by inhibiting the enzyme [[arabinosyl transferase]]. Disruption of the arabinogalactan synthesis inhibits the formation of this complex and leads to increased permeability of the cell wall.


==References==
==References==

Revision as of 13:12, 27 December 2013

Ethambutol Hydrochloride
MYAMBUTOL® FDA Package Insert
Description
Clinical Pharmacology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

MYAMBUTOLEthambutol (commonly abbreviated EMB or simply E) is a bacteriostatic antimycobacterial drug prescribed to treat tuberculosis.[1] It is usually given in combination with other tuberculosis drugs, such as isoniazid, rifampicin and pyrazinamide.

It is sold under the trade names Myambutol and Servambutol.

Category

Antimycobacterial

US Brand Names

MYAMBUTOL

FDA Package Insert

Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Labels and Packages


Mechanism of action

Ethambutol is bacteriostatic against actively growing TB bacilli. It works by obstructing the formation of cell wall. Mycolic acids attach to the 5'-hydroxyl groups of D-arabinose residues of arabinogalactan and form mycolyl-arabinogalactan-peptidoglycan complex in the cell wall. It disrupts arabinogalactan synthesis by inhibiting the enzyme arabinosyl transferase. Disruption of the arabinogalactan synthesis inhibits the formation of this complex and leads to increased permeability of the cell wall.

References

  1. Yendapally R, Lee RE (2008). "Design, synthesis, and evaluation of novel ethambutol analogues". Bioorg. Med. Chem. Lett. 18 (5): 1607–11. doi:10.1016/j.bmcl.2008.01.065. PMC 2276401. PMID 18242089. Unknown parameter |month= ignored (help)